Clinical Trials Directory

Trials / Completed

CompletedNCT00364767

Moderate Alcohol Consumption, Fat and Carbohydrate Metabolism and Insulin Sensitivity

The Effect of Moderate Alcohol Consumption on Markers of Oxidative Phosphorylation and Lipid Oxidation and on Postprandial Glycemic Control in Healthy, Lean and Overweight, Young Men

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
19 (actual)
Sponsor
TNO · Academic / Other
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Moderate alcohol consumption is associated with a decreased risk of diabetes type 2. This association could be mediated by an improvement of insulin sensitivity with moderate alcohol consumption. Patients with diabetes type 2 or impaired glucose tolerance often may have decreased fat oxidative capacity or oxidative phosphorylation in tissue such as muscle. This could lead to accumulation triglyceride storage in muscle, which could interfere with insulin signaling. Whether such mechanism can also play a role with moderate alcohol consumption is unknown and will be investigated in this study. In addition, moderate alcohol consumption with a meal can lead to delayed hypoglycemia in type 1 diabetes patients. How moderate alcohol consumption affects postprandial glycemic response in healthy subjects is unknown. This is a secondary objective of this trial.

Detailed description

To investigate the effect of moderate alcohol consumption on * enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle * transporters of fatty acids and glucose in fat tissue * post-prandial glycemic response in healthy, lean or overweight, young men Design : Open, randomized, partially diet-controlled, placebo controlled cross-over design Participants * Description : Healthy, lean and overweight young (18-40 years) men * Number : 20 Study substances * Test substance : 100 ml whiskey (Famous Grouse, 40% v/v alcohol: ≈ 32 g alcohol) * Reference substance : 100 ml mineral water (Spa blauw) Duration: 2 treatment periods of 4 weeks (28 days) Test parameters: * Muscle biopsy for activity of 3-hydroxy fatty-acyl CoA dehydrogenase, citrate synthase, cytochrome c oxidase * Postprandial glycemic response (glucose, insulin, GLP-1, GLP-2, GIP, glucagon, FFA etc.) * Insulin sensitivity and related factors (oral glucose tolerance test, adiponectin, HbA1c) * Liver enzymes (safety) * Body weight * Urinary ethyl glucuronide (compliance)

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTAAlcohol consumption (32 g/day) for 4 weeks
DIETARY_SUPPLEMENTBWater

Timeline

Start date
2004-10-01
Primary completion
2004-12-01
Completion
2004-12-01
First posted
2006-08-16
Last updated
2008-05-23

Source: ClinicalTrials.gov record NCT00364767. Inclusion in this directory is not an endorsement.